Antitumor activity of 13,14-dihydro-15-deoxy-Δ7-prostaglandin-A1- methyl ester integrated into lipid microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo

Cancer Research

Volumn 59, Issue 16, 1999, Pages 3919-3922

  Sasaki, Hiroshi ^a   Niimi, Shigeki ^b   Akiyama, Minoru ^b   Tanaka, Tadao ^b   Hazato, Atsuo ^b   Kurozumi, Seiji ^b   Fukushima, Shoji ^b   Fukushima, Masanori ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

13,14 DIHYDRO 15 OXOPROSTAGLANDIN E2; CISPLATIN; MICROSPHERE; PROSTAGLANDIN A1;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G1 PHASE; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CROSS RESISTANCE; DRUG EFFECT; FEMALE; GROWTH INHIBITION; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CISPLATIN; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPOSOMES; MICE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PROSTAGLANDINS A;

EID: 0033566762     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. 1-methylester (TEI-9826) to human ovarian cancer cells resistant to cisplatin. Proc. Am. Assoc. Cancer Res., 37: 318, 1996.
2. 2-antitumor and anti-viral activities and mechanisms involved. Ecosanoids, 3: 189-199, 1990.
3. 2 and related compounds: an update. Prostaglandins Leukotrienes Essent. Fatty Acids, 47: 1-12, 1992.
4. 2 and related compounds. Mode of action in G1 arrest and preclinical results. Ann. NY Acad. Sci., 744: 161-165, 1994.
5. 1-methylesters with thiols. J. Am. Chem. Sci., 119: 2376-2385, 1997.
6. 2 is a ligand for the adipocyte determination factor PPARΔ. Cell, 83: 803-812, 1995.
7. 2 metabolite binds peroxisome proliferator-activated receptor Δ and promotes adipocyte differentiation. Cell, 83: 813-819, 1995.
8. 2-mediated cellular arrest and death. Cancer Res., 56: 475-479, 1996.
9. 2. Mol. Cell. Biol., 16: 762-770, 1996.
10. 2. Biochem. Biophys. Res. Commun., 251: 648-652, 1998.
11. Akimaru, K., Nakanishi, M., Suzuki, M., Furuta, K., Noyori, R., and Ishikawa, T. Cell growth inhibition by antitumor prostaglandin and its modulation by MRP/GS-X pump. In: Honn et al. (eds.), Eicosanoids and Other Bioactive Lipids in Cancer Inflammation and Radiation Injury 3. New York: Plenum Publishing Corp., 1997.
12. 2. Gynecol. Oncol., 41: 36-40, 1991.
13. Sasaki, H., and Fukushima, M. Prostaglandins in the treatment of cancer. AntiCancer Drugs, 5: 131-138, 1994.
14. 1 lipid microspheres-pharmaceutical properties and preclinical evaluations. In: T. Yasugi et al. Advances in Polyunsaturated Fatty Acid Research. Amsterdam: Elsevier Science Publishers, 1993.
15. 1 analogues. Proc. Am. Assoc. Cancer Res., 37: 396, 1996.
16. 1 (TEI-9826) integrated in lipid microsphere. Proc. Am. Assoc. Cancer Res., 37: 395, 1996.
17. Suzuki, M., Kiho, T., Tomokiyo, K., Furuta, K., Fukushima, S., Takeuchi, Y., Nakanishi, M., and Noyori, R. Rational design of antitumor prostaglandins with high biological stability. J. Med. Chem., 41: 3084-3090, 1998.
18. 1 analogues. Proc. Am. Assoc. Cancer Res., 39: 315, 1998.
19. 2 in vitro and in vivo. Prostaglandins Leukotorienes Essent. Fatty Acids, 55 (Suppl. 1): 112, 1996.
20. 1 methylester (TEI-9826) integrated in lipid microsphere at various administration routes. Prostaglandins Leukotrienes Essent. Fatty Acids, 55 (Suppl. 1): 112, 1996.
21. Kobori, O., Vuilloyt, M. T., and Martin, F. Growth responses of rat stomach cancer cells to gastro-pancreatic hormones. Int. J. Cancer, 30: 65-67, 1982.
22. 2 is cytotoxic in human malignancies and synergises with both cisplatin and radiation. Cancer Res., 56: 3866-3869, 1996.
23. 2/cisplatin (DDP) synergy in human melanoma cells (T-289) is mediated via an apoptotic mechanism. Proc. Am. Assoc. Cancer Res., 39: 157, 1998.
24. 2 on human colon cancer cell lines. J. Jpn. Cancer Ther., 32: 221-229, 1997 (in Japanese, English abstract).
25. Louie, K. G., Behrens, B. C., Kinsella, T. J., Hamilton, T. C., Grotzinger, K. R., McKoy, W. M., Winker, M. A., and Ozols, R. F. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res., 45: 2110-2115, 1985.
26. Akimaru, K., Kuo, M. T., Furuta, K., Suzuki, M., Noyori, R., and Ishikawa, T. Induction of MRP/GS-X pump and cellular resistance to anticancer prostaglandins. Cytotechnology, 19: 221-227, 1996.
27. Ishikawa, T., Akimaru, K., Ruo, M. T., Nakanishi, M., Tomokiyo, R., Furuta, K., Suzuki, M., and Noyori, R. Anticancer prostaglandin-induced cell cycle arrest and its modulation by a specific inhibitor of MRP/GS-X pump. Proc. Am. Assoc. Cancer Res., 38: 590, 1997.